Skip to main content
. Author manuscript; available in PMC: 2023 Oct 3.
Published in final edited form as: Nat Cell Biol. 2022 Oct 3;24(10):1541–1557. doi: 10.1038/s41556-022-00994-w

Extended Data Fig. 10 ∣. FG1059 induce apoptosis of GBM cells.

Extended Data Fig. 10 ∣

a, In vitro cell viability assay of 022, 157 and 1079 GBM spheres stably expressing RPL22L1a, RPL22L1b or an empty vector. Cells were treated with different concentrations of FG1059 for 5 days (experiment was performed in n = 6 biological replicates; data are mean ± SD). b, FACS analysis of caspase 3/7 activity and SYTOX staining of 157 cells treated with DMSO; 0.2 μM of FG1059; 20 μM of TMZ or with both compounds simultaneously for 24 hours. c, FACS analysis of caspase 3/7 activity and SYTOX staining of 157 cells treated with DMSO; 50 nM of FG1059; 50 nM of Pladienolide B or with both compounds simultaneously for 24 hours. d, Kaplan-Meier curve showing the overall survival of glioma (n = 509 different patients; left panel) and glioblastoma (n = 152 different patients; right panel) patients subdivided based on the RPL22 expression level (log-rank test). Data were obtained from TCGA database. e, Flow cytometry gating used for apoptosis assay (left panel) and for CD133 or HPG staining (right panel).